NewgLab Pharma Appoints Dr. Ko Young-hee, Expert in Immuno-Oncology, as Chairman and President of the Board

[Asia Economy Reporter Hyungsoo Park] Dr. Younghee Ko, an expert in metabolic anticancer agents, has been appointed as the chairman of the board of directors of Newgelab Pharma, a subsidiary of Newgelab.

Newgelab Pharma announced on the 24th that it held a board meeting and appointed Dr. Younghee Ko as the chairman of the board and president to commercialize new metabolic anticancer drugs. Chairman Ko is expected to play a key role not only in Newgelab Pharma's metabolic anticancer drug research and development (R&D) but also in company management.

Chairman Ko earned a master's degree in Nutritional Physiology from Iowa State University and a Ph.D. in Biochemistry from Washington State University. Since 1991, she has served as a core researcher in Professor Peter L. Pedersen’s research team at Johns Hopkins University School of Medicine. She has researched metabolic anticancer substances using 3-bromopyruvate (3BP) for 17 years.

Afterward, Chairman Ko founded Godiscovery and continued R&D to commercialize new metabolic anticancer drugs based on 3BP substances. She has authored over 60 papers in related fields.

Chairman Ko, who served as co-CEO of Newgelab Pharma, which licensed out the metabolic anticancer drug development technology, is now appointed as the chairman of the board and president of Newgelab Pharma.

A company official introduced her as “one of the leaders who, along with Professor Pedersen, succeeded Otto Warburg, the founder of the metabolic anticancer theory, by advancing the theory and elucidating related mechanisms.” The official added, “With the appointment of Chairman Ko as chairman of the board and president, it is expected that she and the scientific advisory committee will communicate closely to accelerate the commercialization of metabolic anticancer drugs.”

In July last year, Newgelab Pharma appointed experts with specialized knowledge and experience in metabolic anticancer agents, including Professor Peter L. Pedersen of Johns Hopkins University School of Medicine and Michael S. Torbenson, M.D., a pathology expert from Mayo Clinic, to its scientific advisory committee.

Also participating are Professor Stanislaw Ulaszewski of the University of Wroclaw in Poland, Professor Adeel Kaiser, M.D., of the University of Maryland School of Medicine, and Professor Dominic D’Agostino of the University of South Florida Morsani College of Medicine.

Newgelab Pharma strengthened its board capabilities by additionally appointing Park Daewoo, CEO of Newgelab, and Lim Jaeseok, Vice President of Newgelab, as directors alongside Chairman Ko and CEO Kim Dong-eun.

This content was produced with the assistance of AI translation services.